Skip to main content
NewslettersWatchlist

Eupraxia Pharmaceuticals Inc(EPRX-T)
TSX

Today's Change
Real-Time Last Update
Day Low4.16
Day High4.29
Open:4.29
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newswire.ca
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
Newswire.ca
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
Newswire.ca
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR Newswire
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
Newswire.ca
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
Baystreet
Stocks in play: Eupraxia Pharmaceuticals Inc.
Newswire.ca
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
PR Newswire
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
Newswire.ca
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
PR Newswire
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
Newswire.ca
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
Newswire.ca
Eupraxia Pharmaceuticals Strengthens Senior Management Team
Newswire.ca
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases
Baystreet
Stocks in play: Eupraxia Pharmaceuticals Inc.
Newswire.ca
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Newswire.ca
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Newswire.ca
Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
Baystreet
Stocks in play: Eupraxia Pharmaceuticals Inc.
Newswire.ca
Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility
Newswire.ca
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
Newswire.ca
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024
AI-generated - The Globe and Mail
Eupraxia Pharmaceuticals: Top 10 Undervalued Growth Stocks on TSX (EPRX)

Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.